Key result
Combining circulating fibrosis biomarkers with CMR accurately diagnoses and predicts outcomes in myocardial fibrosis.
Why the study?
Myocardial fibrosis is a key pathological process driving diastolic dysfunction and pumping failure, necessitating a summary of current approaches to its comprehensive assessment using biochemical, molecular, and imaging parameters.
An integrated approach combining modern laboratory markers of fibrosis with cardiac magnetic resonance imaging provides accurate diagnosis and prognosis of myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
May support integrated fibrosis assessment; leaves open prospective validation before clinical adoption.
Background. Myocardial fibrosis is a key pathophysiological process in a wide range of cardiovascular diseases. It is potentially adaptive in the early stages of cardiac remodelling, but as it progresses, it becomes pathological, leading to increasedmyocardial stiffness, the development of diastolic dysfunction, and deterioration of the heartʼs pumping function. Purpose – to summarize current approaches to the comprehensive assessment of myocardial fibrosis based on biochemical, molecular and imaging parameters and to outline their potential clinical value for diagnosis, prognosis and treatment monitoring. Materials and Methods. A targeted review of publications for 2021–2025 was conducted in the Scopus, Web of Science, and Cochrane Library databases; the search was performed in ScienceDirect and PubMed using specific keywords. Results. It was found that the most informative for non-invasive assessment of fibrosis formation are peptides of collagen synthesis and degradation, which reflect fibroblast activity and collagenolysis and are associated with the severity of remodelling and clinical events; the balance of matrix metalloproteinases and their tissue inhibitors; neurohumoral mediators, in particular transforming growth factor beta, angiotensin II, endothelin I and galectin-3; inflammatory markers and macrophage polarization, which characterize the aggressiveness of fibrosis; small regulatory ribonucleic acids and exosomes as promising tools for potential personalized diagnostics. Magnetic resonance imaging of the heart with delayed gadolinium enhancement and mapping techniques provides a quantitative assessment of both scarring and diffuse interstitial fibrosis. The combination of biomarkers with imaging data provides risk stratification and allows monitoring of response to treatment, particularly with aldosterone antagonists, angiotensin receptor blockers, neprilysin inhibitors, and sodium-dependent glucose cotransporter inhibitors. Conclusions. An integrated approach combining modern laboratory markers of fibrosis with cardiac magnetic resonance imaging results provides accurate diagnosis and prognosis of myocardial fibrosis and contributes to the optimization of personalized therapy
No takes yet. Share an insight, caveat, or question.
Pavliukovych et al. (2025) conducted a review in Myocardial fibrosis. Biochemical, epigenetic and imaging biomarkers was evaluated. An integrated approach combining modern laboratory markers of fibrosis with cardiac magnetic resonance imaging provides accurate diagnosis and prognosis of myocardial fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: